Ethical and policy considerations in the application of pharmacogenomic testing for tardive dyskinesia: Case study of the dopamine D3 receptor

Current Pharmacogenomics and Personalized Medicine

Volumn 9, Issue 2, 2011, Pages 94-101

  Shamy, Michel C F ^a   Zai, Clement ^b   Basile, Vincenzo S ^a,b   Kennedy, James L ^b   Müller, Daniel J ^b   Masellis, Mario ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Canada   (Canada)

Author keywords

DRD3; Ethics; Pharmacogenomics; Prospective policy; Tardive dyskinesia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; FLUPHENAZINE; GLYCINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERINE; ZIPRASIDONE;

AFRICAN AMERICAN; ALLELE; ARTICLE; CAUCASIAN; CHINESE; CLINICAL PRACTICE; CONFIDENTIALITY; DISEASE SEVERITY; DNA POLYMORPHISM; ETHNICITY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GERMANY; GREECE; HEALTH CARE POLICY; HUMAN; INFORMED CONSENT; JAPANESE; KOREA; MEDICAL ETHICS; NIGRONEOSTRIATAL SYSTEM; PHARMACOGENOMICS; RACE; RUSSIAN FEDERATION; SCHIZOPHRENIA; TAIWAN; TARDIVE DYSKINESIA;

EID: 79955678926     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk fac-tors, 1959 to 1979. Arch Gen Psychiatry 1982; 39(4): 473-481.
2. Smith JM, Baldessarini RJ. Changes in prevalence, severity, andrecovery in tardive dyskinesia with age. Arch Gen Psychiatry 1980; 37(12): 1368-1373.
3. Ballesteros J, Gonzalez-Pinto A, Bulbena A. Tardive dyskinesiaassociated with higher mortality in psychiatric patients: results of ameta-analysis of seven independent studies. J Clin Psychopharma-col 2000; 20(2): 188-194.
4. Kulenkampff C, Tarnow G. An unusual syndrome in the oral re-gion caused by administration of megaphen. Nervenarzt 1956;27(4):178-80.
5. Schonecker M. Paroxysmal dyskinesia as the effect of megaphen.Nervenarzt 1957; 28(12): 550-53.
6. Sigwald J, Bouttier D, Raymondeaud C, et al. 4 Cases of faciobucco-linguo-masticatory dyskinesis of prolonged development following treatment with neuroleptics. Rev Neurol (Paris) 1959; 100: 751-55.
7. Faurbye A, Rasch PJ, Petersen PB, et al. Neurological symptoms in pharmacotherapy of psychoses. Acta Psychiatr Scand 1964; 40: 10-27.
8. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 2006; 21(5): 589-98.
9. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975; 188(4194): 1217-9.
10. Masellis M, Basile VS, Ozdemir V, et al. Pharmacogenetics ofantipsychotic treatment: lessons learned from clozapine. Biol Psy-chiatry 2000; 47 (3): 252-266.
11. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesiaassociated with second-generation antipsychotics: a systematic re-view of 1-year studies. Am J Psychiatry 2004; 161(3): 414-425.
12. Basile VS, Masellis M, Badri F, et al. Association of the MscIpolymorphism of the dopamine D3 receptor gene with tardive dy-skinesia in schizophrenia. Neuropsychopharmacology 1999; 21(1):17-27.
13. Steen VM, Lovlie R, MacEwan T, et al. Dopamine D3-receptorgene variant and susceptibility to tardive dyskinesia in schizo-phrenic patients. Mol Psychiatry 1997; 2(2): 139-145.
14. Expert Panel on Detection, Evaluation, and Treatment of HighBlood Cholesterol in Adults (Adult Treatment Panel III). ExecutiveSummary of The Third Report of The National Cholesterol Education Program (NCEP). JAMA 2001; 285(19): 2486-2497.
15. Expert Panel on Detection, Evaluation, and Treatment of HighBlood Cholesterol in Adults (Adult Treatment Panel III) final re-port. Third Report of the National Cholesterol Education Program (NCEP). Circulation 2002; 106(25): 3143-421.
16. Newcomer JW. Metabolic considerations in the use of antipsy-chotic medications: a review of recent evidence. J Clin Psychiatry 2007; 68 (Suppl 1): 20-7.
17. Harris EC, Barraclough B. Excess mortality of mental disorder. BrJ Psychiatry 1998; 173: 11-53.
18. Nuffield Council on Bioethics. Pharmacogenetics: Ethical Issues. London: Nuffield Council on Bioethics. 2003.
19. Pellegrino ED. The ethical use of evidence in biomedicine. EvalHealth Prof 1999; 22(1): 33-43.
20. Hoop JG, Lapid MI, Paulson RM, et al. Clinical and ethical con-siderations in pharmacogenetic testing: views of physicians in 3early adopting departments of psychiatry. J Clin Psychiatry 2010;71(6): 745-753.
21. Cadet JL, Lohr JB. Possible involvement of free radicals in neuro-leptic-induced movement disorders. Evidence from treatment oftardive dyskinesia with vitamin E. Ann N Y Acad Sci 1989; 570:176-185.
22. Muller DJ, Shinkai T, De Luca V, et al. Clinical implications ofpharmacogenomics for tardive dyskinesia. Pharmacogenomics J 2004; 4(2): 77-87.
23. Ozdemir V, Aklillu E, Mee S, et al. Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia andaccess to essential medicines. Expert Opin Pharmacother 2006; 7(2): 119-33.
24. McCreadie RG, Robertson LJ, Wiles DH. The Nithsdale schizo-phrenia surveys. IX: Akathisia, parkinsonism, tardive dyskinesiaand plasma neuroleptic levels. Br J Psychiatry 1992; 160: 793-9.
25. Eastham JH, Lacro JP, Jeste DV. Ethnicity and movement disor-ders. Mt Sinai J Med 1996; 63 (5-6): 314-9.
26. Glazer WM, Morgenstern H, Doucette JT. Predicting the long-termrisk of tardive dyskinesia in outpatients maintained on neurolepticmedications. J Clin Psychiatry 1993; 54(4): 133-9.
27. Glazer WM, Morgenstern H, Doucette J. Race and tardive dyskine-sia among outpatients at a CMHC. Hosp Community Psychiatry 1994; 45(1): 38-42.
28. Holden TJ, Sandler R, Myslobodsky M. Tardive dyskinesia--prevalence and subtypes at Valkenberg Hospital, Cape Town. S AfrMed J 1984; 66(4): 132-4.
29. Kane JM, Woerner M, Borenstein M, et al. Integrating incidenceand prevalence of tardive dyskinesia. Psychopharmacol Bull 1986;22(1): 254-8.
30. Morgenstern H, Glazer WM. Identifying risk factors for tardivedyskinesia among long-term outpatients maintained with neurolep-tic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry 1993; 50(9): 723-733.
31. Swartz JR, Burgoyne K, Smith M, et al. Tardive dyskinesia andethnicity: review of the literature. Ann Clin Psychiatry 1997; 9(1):53-9.
32. Woerner MG, Alvir JM, Saltz BL, et al. Prospective study oftardive dyskinesia in the elderly: rates and risk factors. Am JPsychiatry 1998; 155(11): 1521-8.
33. Wonodi I, Adami HM, Cassady SL, et al. Ethnicity and the courseof tardive dyskinesia in outpatients presenting to the motor disor-ders clinic at the Maryland psychiatric research center. J Clin Psy-chopharmacol 2004; 24(6): 592-8.
34. Jeste DV, Lindamer LA, Evans J, et al. Relationship of ethnicityand gender to schizophrenia and pharmacology of neuroleptics. Psychopharmacol Bull 1996; 32(2): 243-251.
35. Lerer B, Segman RH, Fangerau H, et al. Pharmacogenetics oftardive dyskinesia: combined analysis of 780 patients supports as-sociation with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002; 27(1): 105-119.
36. Bakker PR, van Harten PN, van OJ. Antipsychotic-induced tardivedyskinesia and the Ser9Gly polymorphism in the DRD3 gene: ameta analysis. Schizophr Res 2006; 83(2-3): 185-192.
37. Tsai HT, North KE, West SL, et al. The DRD3 rs6280 polymor-phism and prevalence of tardive dyskinesia: A meta-analysis. Am JMed Genet B Neuropsychiatr Genet 2010; 153B(1): 57-66.
38. Al Hadithy AF, Ivanova SA, Pechlivanoglou P, et al. Tardive dy-skinesia and DRD3, HTR2A and HTR2C gene polymorphisms inRussian psychiatric inpatients from Siberia. Prog Neuropsycho-pharmacol Biol Psychiatry 2009; 33(3): 475-481.
39. Faden RR, Beauchamp TL, King NMP. A History and Theory ofInformed Consent. New York: Oxford University Press. 1986.
40. Peterson-Iyer K. Pharmacogenomics, ethics, and public policy.Kennedy Inst Ethics J 2008; 18(1): 35-56.
41. Ozdemir V. Pharmacogenomics: Reflections on the old and newsocial, ethical, and policy issues in post-genomics medicine. In:Pharmacogenomics in Psychiatry. Basel: Karger 2010; pp. 12-29.
42. Hewitt J. Schizophrenia, mental capacity, and rational suicide. Theor Med Bioeth 2010; 31(1): 63-77.
43. Surles RC. Atypical antipsychotics: considerations for Medicaidcoverage. Am J Manag Care 2005; 11(Suppl 8): S248-53.
44. Solbakk JH, Holm S, Hofmann B. The Ethics of ResearchBiobanking. New York: Springer. 2009.
45. Hope T. Medical Ethics: A Very Short Introduction. Oxford: Ox-ford University Press. 2004.
46. Joly Y, Knoppers BM, Nguyen MT. Stored tissue samples: throughthe confidentiality maze. Pharmacogenomics J 2005; 5(1): 2-5.
47. World Health Organization. WHO Model Lists of Essential Medicines. 2009. Available from: http://www.who.int/selection_medicines/committees/expert/17/sixteenth_adult_list_en.pdf [Ac-cessed February 28, 2011].
48. Seguin B, Essajee S, Jimenez-Sanchez G, et al. Human genomicvariation studies and pharmacogenomics are critical for globalhealth. In: Pharmacogenomics in Admixed Populations. Suarez-Kurtz G, Eds. Georgetown, TX: Landes Bioscience 2007; pp. 198-207.
49. Daar AS, Singer PA. Pharmacogenetics and geographical ancestry:implications for drug development and global health. Nat RevGenet 2005; 6(3): 241-6.
50. Ferdinand KC. Coronary artery disease in minority racial andethnic groups in the United States. Am J Cardiol 2006; 97(2A):12A-9A.
51. Hogerzeil HV. The concept of essential medicines: lessons for richcountries. BMJ 2004; 329(7475): 1169-72.
52. Slovenko R. Update on legal issues associated with tardive dyski-nesia. J Clin Psychiatry 2000; 61(Suppl 4): 45-57.
53. Lee SS, Mountain J, Koenig B, et al. The ethics of characterizingdifference: guiding principles on using racial categories in humangenetics. Genome Biol 2008; 9(7): 404.
54. Lee SS, Mudaliar A. Medicine. Racing forward: the Genomics andPersonalized Medicine Act. Science 2009; 323(5912): 342.
55. Khoury MJ, Gwinn M, Ioannidis JP. The emergence of transla-tional epidemiology: from scientific discovery to population healthimpact. Am J Epidemiol 2010; 172(5): 517-524.
56. Ozdemir V, Basile VS, Masellis M, et al. Pharmacogenetic assess-ment of antipsychotic-induced movement disorders: contribution ofthe dopamine D3 receptor and cytochrome P450 1A2 genes. J Bio-chem Biophys Methods 2001; 47(1-2): 151-7.
57. Basile VS, Masellis M, McIntyre RS, et al. Genetic dissection ofatypical antipsychotic-induced weight gain: novel preliminary dataon the pharmacogenetic puzzle. J Clin Psychiatry 2001; 62(Suppl 23): 45-66.
58. Basile VS, Masellis M, De L,V, et al. 759C/T genetic variation of5HT(2C) receptor and clozapine-induced weight gain. Lancet 2002;360 (9347): 1790-1.
59. Nuffield Council on Bioethics. Medical profiling and online medi-cine: The ethics of personalised healthcare in a consumer age. Lon-don: Nuffield Council on Bioethics. 2010.
60. Rose N. Social and ethical aspects of pharmacogenomics in psy-chiatry. Psychiatry 2007; 6(2): 80-2.
61. Montgomery K. How Doctors Think. Oxford: Oxford UniversityPress. 2006.
62. Khoury MJ, Bradley LA. Why should genomic medicine becomemore evidence-based? Genomic Med 2007; 1(3-4): 91-3.
63. Segman R, Neeman T, Heresco-Levy U, et al. Genotypic associa-tion between the dopamine D3 receptor and tardive dyskinesia inchronic schizophrenia. Mol Psychiatry 1999; 4(3): 247-253.
64. Lovlie R, Daly AK, Blennerhassett R, et al. Homozygosity for theGly-9 variant of the dopamine D3 receptor and risk for tardive dy-skinesia in schizophrenic patients. Int J Neuropsychopharmacol 2000; 3(1): 61-65.
65. Liao DL, Yeh YC, Chen HM, et al. Association between theSer9Gly polymorphism of the dopamine D3 receptor gene andtardive dyskinesia in Chinese schizophrenic patients. Neuropsy-chobiology 2001; 44(2): 95-8.
66. Woo SI, Kim JW, Rha E, et al. Association of the Ser9Gly poly-morphism in the dopamine D3 receptor gene with tardive dyskine-sia in Korean schizophrenics. Psychiatry Clin Neurosci 2002;56(4): 469-474.
67. Chong SA, Tan EC, Tan CH, et al. Polymorphisms of dopaminereceptors and tardive dyskinesia among Chinese patients withschizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003;116B(1): 51-54.
68. Zhang ZJ, Zhang XB, Hou G, et al. Interaction between polymor-phisms of the dopamine D3 receptor and manganese superoxidedismutase genes in susceptibility to tardive dyskinesia. PsychiatrGenet 2003; 13(3): 187-192.
69. de Leon J, Susce MT, Pan RM, et al. Polymorphic variations inGSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 andD3 receptors and their association with tardive dyskinesia in severemental illness. J Clin Psychopharmacol 2005; 25(5): 448-456.
70. Rizos EN, Siafakas N, Katsantoni E, et al. Association of the do-pamine D3 receptor Ser9Gly and of the serotonin 2C receptor genepolymorphisms with tardive dyskinesia in Greeks with chronicschizophrenic disorder. Psychiatr Genet 2009; 19(2): 106-107.